Innoviva, Inc. (NASDAQ:INVA)’s share price dropped 15.6% during trading on Wednesday following a dissappointing earnings announcement. The stock traded as low as $11.47 and last traded at $11.73. Approximately 3,125,178 shares traded hands during mid-day trading, an increase of 201% from the average daily volume of 1,038,160 shares. The stock had previously closed at $13.89.
The biotechnology company reported $0.21 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.13). The company had revenue of $48.64 million for the quarter, compared to analysts’ expectations of $57.18 million. Innoviva had a net margin of 52.91% and a negative return on equity of 30.87%. The firm’s revenue was up 46.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.13 earnings per share.
A number of equities analysts have recently issued reports on INVA shares. ValuEngine raised Innoviva from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Cowen and Company set a $16.00 price target on Innoviva and gave the stock a “buy” rating in a report on Friday, July 28th. Zacks Investment Research upgraded Innoviva from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Wednesday. Robert W. Baird restated a “hold” rating and issued a $13.00 price target on shares of Innoviva in a report on Tuesday. Finally, Stifel Nicolaus restated a “hold” rating and issued a $15.00 price target on shares of Innoviva in a report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. Innoviva currently has a consensus rating of “Hold” and an average price target of $13.60.
Several institutional investors and hedge funds have recently added to or reduced their stakes in INVA. Ameritas Investment Partners Inc. grew its holdings in shares of Innoviva by 868.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 7,328 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 6,571 shares during the period. Victory Capital Management Inc. acquired a new stake in Innoviva during the 1st quarter valued at $117,000. Cubist Systematic Strategies LLC grew its holdings in Innoviva by 37.8% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 13,005 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 3,569 shares during the last quarter. Profund Advisors LLC grew its holdings in Innoviva by 8.8% during the 2nd quarter. Profund Advisors LLC now owns 15,220 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 1,227 shares during the last quarter. Finally, State of Alaska Department of Revenue grew its holdings in Innoviva by 79.1% during the 2nd quarter. State of Alaska Department of Revenue now owns 15,327 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 6,767 shares during the last quarter. Institutional investors and hedge funds own 69.72% of the company’s stock.
The company’s 50 day moving average price is $13.90 and its 200 day moving average price is $13.00. The company has a market cap of $1.33 billion, a PE ratio of 15.26 and a beta of 2.60.
ILLEGAL ACTIVITY NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright law. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/10/27/innoviva-inc-inva-shares-down-15-6-after-earnings-miss.html.
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.